11-Sep-2026
TipRanks (Thu, 10-Sep 6:30 AM ET)
TipRanks (Wed, 9-Sep 6:20 AM ET)
FDA names acting heads of drug and vaccine units to permanent roles
Seeking Alpha News (Tue, 8-Sep 8:25 PM ET)
Abbott granted FDA nod for advanced cardiac ablation catheter
Seeking Alpha News (Tue, 8-Sep 8:30 AM ET)
PRNewswire (Tue, 8-Sep 8:00 AM ET)
Boston Scientific Stock (BSX) Slides as Cyberattack Set to Batter Full-Year Profits
TipRanks (Tue, 8-Sep 7:18 AM ET)
PRNewswire (Mon, 31-Aug 8:01 AM ET)
PRNewswire (Thu, 27-Aug 9:00 AM ET)
PRNewswire (Tue, 25-Aug 2:51 PM ET)
PRNewswire (Thu, 20-Aug 4:15 PM ET)
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Abbott Laboratories trades on the NYSE stock market under the symbol ABT.
As of September 11, 2026, ABT stock price declined to $101.95 with 7,922,860 million shares trading.
ABT has a beta of -0.32, meaning it tends to be less sensitive to market movements. ABT has a correlation of 0.02 to the broad based SPY ETF.
ABT has a market cap of $176.41 billion. This is considered a Large Cap stock.
Last quarter Abbott Laboratories reported $13 billion in Revenue and $1.31 earnings per share. This beat revenue expectation by $83 million and exceeded earnings estimates by $.03.
In the last 3 years, ABT traded as high as $141.23 and as low as $81.97.
The top ETF exchange traded funds that ABT belongs to (by Net Assets): VTI, SCHD, VOO, SPY, VTV.
ABT has underperformed the market in the last year with a price return of -21.3% while the SPY ETF gained +17.4%. However, in the short term, ABT had mixed performance relative to the market. It has outperformed in the last 3 months, returning +14.4% vs +3.9% return in SPY. But in the last 2 weeks, ABT shares have been beat by the market, returning -9.4% compared to an SPY return of -0.7%.
ABT support price is $101.71 and resistance is $105.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABT shares will trade within this expected range on the day.